on Zomedica Corp. (NASDAQ:ZOM)
Zomedica Reports 14% Revenue Growth in Q2 2025
Zomedica Corp., a veterinary health company, announced a 14% revenue increase to $7 million in Q2 2025, marking the 18th consecutive quarter of record year-over-year revenue growth. CEO Larry Heaton highlighted the strong performance of their therapeutic and diagnostic products, including PulseVet® and TRUFORMA®, which spurred this growth.
The Diagnostic segment grew by 86%, while Consumable sales rose by 21%, underpinning future recurring revenue opportunities. International sales improved by 13% from Q2 2024, fueled by both organic growth and new distributor partnerships. The company maintained healthy gross margins at 67%.
Operational costs reduced by $0.7 million due to ongoing internal cost-reduction initiatives. Zomedica reported a net loss of $7.4 million for the quarter, considerably lower than the $23.9 million loss seen in Q2 2024. The company's strategic focus remains on expanding its product portfolio internationally.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Zomedica Corp. news